Novartis Seeks COVID-19 Antiviral Candidate Authorization
February 10, 2022 • 11:24 am CST
(Precision Vaccinations)
Switzerland-based Molecular Partners AG today announced
its partner Novartis
had requested Emergency Use Authorization from the U.S. FDA for ensovibep,
a DARPin antiviral therapeutic candidate to treat COVID-19.
Ensovibep is explicitly designed to inhibit target cell
entry of the SARS-CoV-2 beta coronavirus.
This FDA
submission is based on the totality of clinical and preclinical studies data,
including the positive results of the Phase 2 portion of the EMPATHY study.
This randomized, placebo-controlled study enrolled 407 symptomatic patients
infected with SARS-CoV-2.
DARPins (Designed Ankyrin Repeat Proteins) are mono or
multi-specific protein-based therapies designed to engage their targets for
various effects specifically.
Ensovibep includes three covalently linked individual
DARPin domains that bind to the spike protein of SARS-CoV-2.
With these domains incorporated into a single molecule,
ensovibep is designed to block the receptor-binding domain of the
SARS-CoV-2 spike protein, even in the presence of some mutations of the spike
protein.
Several characteristics of DARPin therapeutics make them
potentially suitable for COVID-19 treatment, including multi-specific binding,
the rapid onset of action, and scalable bacterial production.
"We are pleased that the results from the EMPATHY
trial demonstrate the positive therapeutic effect of ensovibep, with the
potential to be an important new treatment option to combat the rapidly
evolving SARS-CoV-2 pandemic," commented Vas Narasimhan, CEO
of Novartis, in a press release issued on January 10, 2022.
"As COVID-19 continues to burden healthcare systems
across the globe, a range of treatments will be needed, and Novartis is proud
to continue our collaboration with Molecular Partners on this unique treatment
for COVID-19 and contribute ensovibep to this suite of options."
Molecular Partners and Novartis entered into a license agreement on January 18, 2022, under which Novartis in-licensed global rights to ensovibep.
Connecting the Dots:
Novartis Corporation is a U.S.
subsidiary of Novartis AG and a
member of the Pharmaceutical Research and
Manufacturers of America.
Akin, Gump, Strauss, Hauer & Feld, LLP is
the lobby firm for the Novartis Corporation
and the Pharmaceutical Research and
Manufacturers of America.
Vernon E. Jordan
Jr. is a senior counsel
for Akin, Gump, Strauss, Hauer & Feld,
LLP and an honorary trustee at the Brookings
Institution (think tank).
Foundation to Promote Open Society was
a funder for the Brookings Institution
(think tank) and the Carnegie
Endowment for International Peace (think tank).
George Soros was the chairman
for the Foundation to Promote Open Society.
James F. Collins is
a senior associate at the Carnegie
Endowment for International Peace (think tank) and was a senior
advisor for Akin, Gump, Strauss, Hauer
& Feld, LLP.
Ed Griffin’s interview with Norman Dodd in 1982
(The investigation into the Carnegie
Endowment for International Peace uncovered the plans for “Population Control”
by involving the United States in war)
http://www.illuminati-news.com/110106a.htm
Donald Kennedy was
a trustee at the Carnegie Endowment for
International Peace (think tank) and a commissioner for the U.S. Food and Drug Administration (FDA).
William W. George is
a trustee at the Carnegie Endowment for
International Peace (think tank) and was a director at Novartis AG.
Daniel Vasella is
a trustee at the Carnegie Endowment for
International Peace (think tank) and was the chairman for Novartis AG.
Carnegie Endowment for International Peace (think
tank) was a funder for the Nuclear
Threat Initiative (think tank).
Margaret A.
Hamburg is a VP for the Nuclear
Threat Initiative (think tank) and the commissioner for the U.S. Food and Drug Administration (FDA).
Jessica
Tuchman Mathews is a director at the Nuclear
Threat Initiative (think tank), the president of the Carnegie Endowment for International Peace (think tank),
was an honorary trustee at the Brookings
Institution (think tank).
Foundation to Promote Open Society was
a funder for the Carnegie Endowment for
International Peace (think tank) and the Brookings Institution (think tank).
George Soros was the chairman
for the Foundation to Promote Open Society.
Mark B. McClellan was
a senior fellow at the Brookings
Institution (think tank) and a commissioner for the U.S. Food and Drug Administration (FDA).
Ann
M. Fudge is a trustee at the Brookings
Institution (think tank) and a director at Novartis AG.
Klaus Kleinfeld is
a trustee at the Brookings Institution (think
tank) and a trustee at the Conference
Board (think tank).
Marjorie M.T.
Yang was a trustee at the Conference
Board (think tank) and is a
director at Novartis AG.
Novartis Corporation is a U.S. subsidiary of Novartis AG and a member of the Pharmaceutical Research and Manufacturers of America.
Resources: Past Research
Neurologist Claims
There Is No Such Thing as ADHD (Past Research on Novartis
AG)
THURSDAY, MARCH 13, 2014
https://thesteadydrip.blogspot.com/2014/03/neurologist-claims-there-is-no-such.html
No comments:
Post a Comment